Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Itacitinib 300/200 mg	7
Overall Study	STARTED	Itacitinib 400/300 mg	7
Overall Study	STARTED	Itacitinib 600/400 mg	8
Overall Study	STARTED	Other	1
Overall Study	COMPLETED	Itacitinib 300/200 mg	6
Overall Study	COMPLETED	Itacitinib 400/300 mg	2
Overall Study	COMPLETED	Itacitinib 600/400 mg	3
Overall Study	COMPLETED	Other	1
Overall Study	NOT COMPLETED	Itacitinib 300/200 mg	1
Overall Study	NOT COMPLETED	Itacitinib 400/300 mg	5
Overall Study	NOT COMPLETED	Itacitinib 600/400 mg	5
Overall Study	NOT COMPLETED	Other	0

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03978637/flow